Delving into the Latest Updates on Chengdu Zhitian Bioengineering Co., Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Digestive System Disorders

Neoplasms

Growth factors

Biosimilar

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Growth factors	1
Biosimilar	1

Top 5 Target	Count

FGFR2(Fibroblast growth factor receptor 2)	1

The main purpose is to investigate the tolerance of lyophilized recombinant human keratinocyte growth factor and explore the maximum tolerated dose in patients with blood malignancies who are receiving autologous hematopoietic stem cell transplantation, followed by preliminary exploration of efficacy and evaluation of pharmacokinetic characteristics.

Start Date26 May 2015

Sponsor / Collaborator

Chengdu Bofa Biotechnology Co Ltd

[+1]

CTR20132639 / CompletedPhase 1

冻干重组人角质细胞生长因子在健康受试者I期临床耐受性、药代动力学及初步药效学试验

[Translation] Phase I clinical tolerability, pharmacokinetics and preliminary pharmacodynamics study of lyophilized recombinant human keratinocyte growth factor in healthy subjects

考察健康受试者接受单次和多次注射不同剂量冻干重组人角质细胞生长因子的耐受性、药代动力学及初步药效学。

[Translation]

To investigate the tolerability, pharmacokinetics and preliminary pharmacodynamics of single and multiple injections of different doses of freeze-dried recombinant human keratinocyte growth factor in healthy subjects.

Start Date08 Jan 2013

Sponsor / Collaborator

Chengdu Bofa Biotechnology Co Ltd

[+1]

100 Clinical Results associated with Chengdu Zhitian Bioengineering Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Chengdu Zhitian Bioengineering Co., Ltd.

Login to view more data

100 Deals associated with Chengdu Zhitian Bioengineering Co., Ltd.

Login to view more data

100 Translational Medicine associated with Chengdu Zhitian Bioengineering Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Palifermin biosimilar(Chengdu Zhitian Biological Engineering Co Ltd) ( FGFR2 )	Mucositis More	Phase 2
Recombinant glucagon-like peptide-1 receptor agonist(Chengdu Zhitian Biological Engineering Co Ltd) ( GLP-1R )	Diabetes Mellitus, Type 2 More	Discontinued